



Aurobindo Pharma receives approval for Simvastatin Tablets from TGA, Australia

Aurobindo Pharma Limited is pleased to announce that its wholly owned subsidiary Aurobindo Pharma Australia Pty Ltd has received yet another approval from the Therapeutic Goods Administration (TGA), Government of Australia for the registration of Simvastatin Tablets 5, 10, 20, 40 & 80 mg

Simvastatin is indicated in patients at high risk of coronary heart disease (CHD) (with or without hypercholesterolemia) and falls under the Cardiovascular (CVS) therapeutic segment.

This is Aurobindo's third approval from TGA, Australia.

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, WHO, Health Canada, MCC South Africa, ANVISA Brazil. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up. The Company is marketing these products globally, in over 100 countries..

For further information, please contact:

Investor Relations

Aurobindo Pharma Limited

Reg Off: Plot No. 2, Maitrivihar, Ameerpet, Hyderabad

Phone: 040-66725000 / 66725401

Email: ir@aurobindo.com